DICE Therapeutics, Inc. (DICE): Price and Financial Metrics
GET POWR RATINGS... FREE!
DICE Stock Price Chart Interactive Chart >
DICE Price/Volume Stats
| Current price | $14.99 | 52-week high | $40.50 |
| Prev. close | $14.49 | 52-week low | $13.39 |
| Day low | $13.97 | Volume | 813,900 |
| Day high | $15.13 | Avg. volume | 332,246 |
| 50-day MA | $18.63 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 573.05M |
DICE Therapeutics, Inc. (DICE) Company Bio
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is S011806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4Ã7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVÃ1/aVÃ6 integrin for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Latest DICE News From Around the Web
Below are the latest news stories about DICE Therapeutics Inc that investors may wish to consider to help them evaluate DICE as an investment opportunity.
What Type Of Shareholders Own The Most Number of DICE Therapeutics, Inc. (NASDAQ:DICE) Shares?Every investor in DICE Therapeutics, Inc. ( NASDAQ:DICE ) should be aware of the most powerful shareholder groups... |
DICE Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will present at the 11 th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17 at 4:20 p.m. ET. |
DICE Therapeutics, Inc. (NASDAQ:DICE) may have lost US$125m in value but insiders who invested last year have seen gains of around US$45k to dateInsiders who bought DICE Therapeutics, Inc. ( NASDAQ:DICE ) in the last 12 months may probably not pay attention to the... |
DICE Therapeutics (NASDAQ:DICE) Trading Up 3.1%DICE Therapeutics Inc (NASDAQ:DICE) was up 3.1% on Tuesday . The company traded as high as $30.02 and last traded at $27.86. Approximately 725,139 shares traded hands during trading, an increase of 277% from the average daily volume of 192,514 shares. The stock had previously closed at $27.01. Several research firms have recently commented on [] |
DICE Therapeutics to Present at November Investor ConferencesSOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced that management will participate in the following investor conferences in November: 33rd Annual Piper Sandler Virtual Healthcare Conference. A pre-recorded fireside chat with DICE |
DICE Price Returns
| 1-mo | -25.24% |
| 3-mo | -20.81% |
| 6-mo | -52.22% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -40.77% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...